Scholarlink

Purpose of Review <p>Restless legs syndrome (RLS) significantly impacts patients’ quality of life and requires effective management strategies. While dopaminergic agonists have been widely used in the past, concerns about symptom augmentation highlight the need for alternative therapies.</p> Recent Findings <p>Non-dopaminergic agents, such as α2δ ligands and iron supplementation, are viable alternatives with favorable safety profiles. A comprehensive approach that includes non-pharmacological measures, individualized treatment plans, and regular monitoring for iron deficiency is essential for optimal symptom management.</p> Summary <p>We present a treatment plan using iron replacement and long-term use of non-dopaminergic agents. Dopamine agonists are reserved for specific, time-limited situations only, while opioids should be kept for treatment-resistant cases. As research advances, future RLS management will likely be individualized, further enhancing therapeutic outcomes and ultimately improving patients’ overall quality of life.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacological Strategies for the Treatment of Restless Legs Syndrome

  • 期刊论文

  • 发表日期：

    2025年8月19日

查看全文
  • David Anguizola,
  • Alba Garcia Aragón,
  • Alejandro Lopez Jimenez,
  • Valentin Sainz,
  • Diego Garcia-Borreguero

摘要

Purpose of Review

Restless legs syndrome (RLS) significantly impacts patients’ quality of life and requires effective management strategies. While dopaminergic agonists have been widely used in the past, concerns about symptom augmentation highlight the need for alternative therapies.

Recent Findings

Non-dopaminergic agents, such as α2δ ligands and iron supplementation, are viable alternatives with favorable safety profiles. A comprehensive approach that includes non-pharmacological measures, individualized treatment plans, and regular monitoring for iron deficiency is essential for optimal symptom management.

Summary

We present a treatment plan using iron replacement and long-term use of non-dopaminergic agents. Dopamine agonists are reserved for specific, time-limited situations only, while opioids should be kept for treatment-resistant cases. As research advances, future RLS management will likely be individualized, further enhancing therapeutic outcomes and ultimately improving patients’ overall quality of life.